Eric R. Kandel M.D.

 
  • Awarded Nobel Prize for Physiology or Medicine in 2000 and National Medal of Science of USA
  • Professor of Neuroscience at Columbia University, Fred Kavli Professor and Director, Kavli Institute for Brain Sciences
  • Senior Investigator at Howard Hughes Medical Institute, Graduate of Harvard and N.Y.U. School of Medicine, Trained in Neurobiology at NIH and Psychiatry at Harvard Medical School

Jorge Costa M.D., Ph.D.

Founding Director

 
  • President of the Brazilian Brain Institute, INBRACER
  • President/Exec Dir. of World Psychiatric Association (WPA) 1983-1993 and lifetime council member
  • International Director of World Health Organization (Geneva) 1993-2000
  • Senior Scientist of the International Center against Mental Illness (ICAMI), New York University affiliated center

Jorge Kalil M.D., Ph.D.

 
  • Professor of Medicine, Head of Clinical Immunology and Allergy and Director of Immunology Lab at the Heart Institute, School of Medicine, University of Sao Paulo
  • President of Butantan Institute (leading Brazilian biomedical research center and immunobiologicals producer)
  • President (2013 to 2016) of IUIS – International Union of Immunology Societies

Raymond F. Schinazi Ph.D., D.Sc.

 
  • Professor of Pediatrics and Chemistry; Director, Laboratory of Biochemical Pharmacology, Emory's Center for AIDS Research, Emory University
  • Founder of several companies, including Pharmasset Inc., Triangle Pharma, Idenix Pharma and RFS Pharma LLC
  • Authored over 500 peer reviewed papers, 7 books and holds over 92 issued U.S. Patents which have resulted in 12 NDAs

Samuel Broder M.D.

 
  • Member of the Institute of Medicine of the U.S. National Academy of Sciences, is the author of more than 340 scholarly papers, and holds numerous patents
  • Senior Leadership positions at Celera
  • Former Director of National Cancer Institute (NCI) from 1989 to 1995.
  • Co-developer of some of the first effective AIDs drugs
 

Peter Hirth Ph.D.

Peter-Hirth.Ph-D  
  • Co-founded and served as CEO of Plexxikon until it was sold to Daiichi Sankyo; advanced several NCEs into the clinic, including Zelboraf through FDA approval
  • Former President of Sugen (Pharmacia; Pfizer); advanced Sutent through FDA approval
  • Previously held VP of Research Immuno-pharmacology position at Boehringer Mannheim GmbH
  • Peter received his Ph.D. in molecular genetics at Heidelberg University, completed his postdoctoral work at the University of California, San Diego and was a research scientist at the Max Planck Institute